Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
cabiralizumab (BMS-986227)
i
Other names:
BMS-986227, FPA008, ONO-4687, FPA-008
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Amgen, BMS, Ono Pharma
Drug class:
CSF-1R inhibitor
Related drugs:
‹
avapritinib (13)
TPX-0022 (8)
pexidartinib (6)
pacritinib (3)
HX301 (2)
vorolanib (1)
OPN-7486 (1)
CS 2164 (1)
ABSK021 (1)
AMB-05X (0)
C019199 (0)
HH185 (0)
LY3022855 (0)
NMS-088 (0)
axatilimab-csfr (0)
SU 14813 (0)
SYHA1813 (0)
Q702 (0)
SYHA1817 (0)
BLZ-945 (0)
DCC-3014 (0)
avapritinib (13)
TPX-0022 (8)
pexidartinib (6)
pacritinib (3)
HX301 (2)
vorolanib (1)
OPN-7486 (1)
CS 2164 (1)
ABSK021 (1)
AMB-05X (0)
C019199 (0)
HH185 (0)
LY3022855 (0)
NMS-088 (0)
axatilimab-csfr (0)
SU 14813 (0)
SYHA1813 (0)
Q702 (0)
SYHA1817 (0)
BLZ-945 (0)
DCC-3014 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
TMB-L
Pancreatic Cancer
TMB-L
Pancreatic Cancer
nivolumab + BMS-986227
Sensitive: C3 – Early Trials
nivolumab + BMS-986227
Sensitive
:
C3
nivolumab + BMS-986227
Sensitive: C3 – Early Trials
nivolumab + BMS-986227
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login